[go: up one dir, main page]

SI3788044T1 - Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo - Google Patents

Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo

Info

Publication number
SI3788044T1
SI3788044T1 SI201930598T SI201930598T SI3788044T1 SI 3788044 T1 SI3788044 T1 SI 3788044T1 SI 201930598 T SI201930598 T SI 201930598T SI 201930598 T SI201930598 T SI 201930598T SI 3788044 T1 SI3788044 T1 SI 3788044T1
Authority
SI
Slovenia
Prior art keywords
making
methods
same
inhibitory compounds
rip1
Prior art date
Application number
SI201930598T
Other languages
English (en)
Inventor
Esteban Masuda
Simon Shaw
Vanessa Taylor
Somasekhar Bhamidipati
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of SI3788044T1 publication Critical patent/SI3788044T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201930598T 2018-05-03 2019-05-02 Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo SI3788044T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666462P 2018-05-03 2018-05-03
PCT/US2019/030476 WO2019213447A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same
EP19724048.4A EP3788044B1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (1)

Publication Number Publication Date
SI3788044T1 true SI3788044T1 (sl) 2023-12-29

Family

ID=66530556

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930598T SI3788044T1 (sl) 2018-05-03 2019-05-02 Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo

Country Status (38)

Country Link
US (8) US10815206B2 (sl)
EP (2) EP3788044B1 (sl)
JP (4) JP2021523226A (sl)
KR (1) KR102808215B1 (sl)
CN (4) CN120535513A (sl)
AU (2) AU2019262144B2 (sl)
BR (1) BR112020022420A2 (sl)
CA (1) CA3099037A1 (sl)
CL (1) CL2020002841A1 (sl)
CO (1) CO2020015156A2 (sl)
CR (1) CR20200581A (sl)
DK (1) DK3788044T3 (sl)
DO (2) DOP2020000198A (sl)
EA (1) EA202092580A1 (sl)
EC (1) ECSP20078326A (sl)
ES (1) ES2956087T3 (sl)
FI (1) FI3788044T3 (sl)
HR (1) HRP20231381T1 (sl)
HU (1) HUE063896T2 (sl)
IL (2) IL278417B2 (sl)
JO (1) JOP20200278A1 (sl)
LT (1) LT3788044T (sl)
MA (1) MA52488B1 (sl)
MD (1) MD3788044T2 (sl)
MX (1) MX2020011621A (sl)
MY (1) MY208132A (sl)
PE (1) PE20211383A1 (sl)
PH (1) PH12020551847A1 (sl)
PL (1) PL3788044T3 (sl)
PT (1) PT3788044T (sl)
RS (1) RS64736B1 (sl)
SA (1) SA520420468B1 (sl)
SG (1) SG11202010915XA (sl)
SI (1) SI3788044T1 (sl)
SM (1) SMT202300313T1 (sl)
UA (1) UA128369C2 (sl)
WO (1) WO2019213447A1 (sl)
ZA (2) ZA202007486B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523226A (ja) 2018-05-03 2021-09-02 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
US10975064B2 (en) 2018-05-03 2021-04-13 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
CN111138448B (zh) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
US12365695B2 (en) * 2019-08-09 2025-07-22 Bisichem Co., Ltd. Fused ring heteroaryl compounds as RIPK1 inhibitors
PH12022550537A1 (en) 2019-09-06 2023-03-20 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same.
BR112022002580A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
US11790111B2 (en) * 2019-10-21 2023-10-17 Google Llc Verifiable consent for privacy protection
FI4055021T3 (fi) 2019-11-07 2025-12-16 Rigel Pharmaceuticals Inc Heterosyklisiä rip1:tä estäviä yhdisteitä
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
CN115515940A (zh) * 2020-02-28 2022-12-23 德州大学系统董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
AR121717A1 (es) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
WO2022171111A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
CN114989156B (zh) * 2021-05-19 2024-07-05 成都贝诺科成生物科技有限公司 一种受体相互作用蛋白抑制剂及其制备方法和用途
KR102707109B1 (ko) 2021-08-10 2024-09-20 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
US20250019372A1 (en) * 2021-12-16 2025-01-16 Rigel Pharmaceuticals, Inc. Crystalline forms of a ripk1 inhibitor
WO2023138317A1 (zh) * 2022-01-21 2023-07-27 中国科学院上海药物研究所 具有ripk1抑制活性的化合物、其制备方法及其用途
WO2023174374A1 (zh) * 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
CN114736197B (zh) * 2022-06-13 2022-09-13 南京医工医药技术有限公司 咪唑啉酮衍生物及其用途
CN115353513A (zh) * 2022-07-29 2022-11-18 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用
US20250000872A1 (en) 2023-06-26 2025-01-02 Eli Lilly And Company Formulations and dosing regimens for rip1 kinase inhibitors for treating autoimmune and inflammatory diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DE69009946T2 (de) 1989-12-04 1994-11-03 Searle & Co System zur transdermalen Albuterol Applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US20090099242A1 (en) 2007-08-15 2009-04-16 Cuny Gregory D Heterocyclic inhibitors of necroptosis
TWI638815B (zh) * 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
EP3256467A1 (en) 2015-02-13 2017-12-20 GlaxoSmithKline Intellectual Property Management Limited Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
SG10201913880XA (en) * 2015-07-02 2020-03-30 Hoffmann La Roche Bicyclic lactams and methods of use thereof
DK3362449T3 (da) 2015-10-13 2021-07-19 Inst Nat Sante Rech Med Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
US10787462B2 (en) 2015-10-23 2020-09-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
TWI781920B (zh) * 2016-02-05 2022-11-01 美商戴納立製藥公司 化合物、組合物及方法
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP2020509009A (ja) * 2017-02-27 2020-03-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としての複素環式アミド
US10975064B2 (en) * 2018-05-03 2021-04-13 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
JP2021523226A (ja) * 2018-05-03 2021-09-02 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
EP3816163A4 (en) 2018-06-26 2022-04-13 Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
BR112022002580A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
PL3788044T3 (pl) 2024-02-12
JP2022160665A (ja) 2022-10-19
US11472782B2 (en) 2022-10-18
US20210002237A1 (en) 2021-01-07
JP7187729B2 (ja) 2022-12-12
JP7367169B2 (ja) 2023-10-23
HRP20231381T1 (hr) 2024-03-01
EP3788044A1 (en) 2021-03-10
JP7735368B2 (ja) 2025-09-08
EP3788044B1 (en) 2023-08-09
US11377428B2 (en) 2022-07-05
RS64736B1 (sr) 2023-11-30
ES2956087T3 (es) 2023-12-13
BR112020022420A2 (pt) 2021-03-02
DOP2023000169A (es) 2023-10-15
CA3099037A1 (en) 2019-11-07
MY208132A (en) 2025-04-17
EP4248975A3 (en) 2024-03-13
JP2023022225A (ja) 2023-02-14
AU2023254980A1 (en) 2023-11-16
CN120535513A (zh) 2025-08-26
IL278417A (sl) 2020-12-31
PT3788044T (pt) 2023-08-31
LT3788044T (lt) 2023-11-10
UA128369C2 (uk) 2024-06-26
SG11202010915XA (en) 2020-12-30
JP2024009916A (ja) 2024-01-23
US20230113841A1 (en) 2023-04-13
CN120535512A (zh) 2025-08-26
CL2020002841A1 (es) 2021-05-24
US20210002236A1 (en) 2021-01-07
IL278417B1 (en) 2024-01-01
FI3788044T3 (fi) 2023-09-25
US20210238153A2 (en) 2021-08-05
PE20211383A1 (es) 2021-07-27
EA202092580A1 (ru) 2021-04-07
DOP2020000198A (es) 2021-04-30
EP4248975A2 (en) 2023-09-27
IL299784B1 (en) 2023-12-01
JP2021523226A (ja) 2021-09-02
KR20210005222A (ko) 2021-01-13
MD3788044T2 (ro) 2023-12-31
US11370764B2 (en) 2022-06-28
CN120535514A (zh) 2025-08-26
KR102808215B1 (ko) 2025-05-19
SA520420468B1 (ar) 2024-04-28
US20210009537A1 (en) 2021-01-14
US20250034100A1 (en) 2025-01-30
SMT202300313T1 (it) 2024-01-10
US20190337907A1 (en) 2019-11-07
MX2020011621A (es) 2021-02-22
WO2019213447A1 (en) 2019-11-07
CO2020015156A2 (es) 2021-02-26
PH12020551847A1 (en) 2021-06-28
AU2019262144A1 (en) 2020-11-26
IL299784B2 (en) 2024-04-01
MA52488B1 (fr) 2023-11-30
US12116354B2 (en) 2024-10-15
NZ770295A (en) 2025-05-30
MA52488A (fr) 2021-03-10
CN112368278B (zh) 2025-06-17
US10815206B2 (en) 2020-10-27
JOP20200278A1 (ar) 2020-11-03
AU2019262144B2 (en) 2023-11-16
ECSP20078326A (es) 2021-03-31
US20210040053A1 (en) 2021-02-11
IL299784A (en) 2023-03-01
US11332451B2 (en) 2022-05-17
CR20200581A (es) 2021-05-11
CN112368278A (zh) 2021-02-12
DK3788044T3 (da) 2023-10-02
US11370765B2 (en) 2022-06-28
AU2023254980B2 (en) 2025-09-18
US20200407332A1 (en) 2020-12-31
ZA202108603B (en) 2022-03-30
HUE063896T2 (hu) 2024-02-28
ZA202007486B (en) 2022-06-29
IL278417B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
ZA202108603B (en) Rip1 inhibitory compounds and methods for making and using the same
IL291033A (en) rip1 inhibitory compounds and methods for their preparation and use
ZA202007487B (en) Rip1 inhibitory compounds and methods for making and using the same
IL290781A (en) rip1 inhibitory compounds and methods for their preparation and use
IL277502A (en) Compounds and uses for them
PL3594199T3 (pl) Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
EP3899293C0 (en) LOCK NUT
SG11202009138QA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
SG11202009175RA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
IL279483A (en) Cyanotriazole compounds and their uses
EP3724933A4 (en) SUPRAL CONDUCTING COMPOUNDS AND METHOD FOR PRODUCING THEREOF
IL283309A (en) rip1 inhibitors
HK40124048A (zh) Rip1抑制性化合物以及制备和使用其的方法
HK40124049A (zh) Rip1抑制性化合物以及制备和使用其的方法
HK40067714A (en) Rip1 inhibitory compounds and methods for making and using the same
GB201917427D0 (en) The flylead
GB201916822D0 (en) The degravitator
ZA201906782B (en) Mulcher
HK40043702A (en) Cyanotriazole compounds and uses thereof
HK40046130A (en) Compounds and uses thereof
HK40040535A (en) Superconducting compounds and methods for making the same
HK40046944A (en) Pladienolide compounds and their use
HK40046919A (en) Compounds and uses thereof
GB201902293D0 (en) The hangit
HUE059374T2 (hu) Tumbler és az üzemeltetésére szolgáló eljárás